• Urology

Timothy J. Daskivich, MD, MSHPM, is a urologic oncologist in the Cedars-Sinai Urology Academic Program and the director of Health Services Research for the Cedars-Sinai Department of Surgery. His clinical practice includes surgical treatment of cancers of the prostate, kidney, bladder and testis, with a focus on prostate cancer. Dr. Daskivich completed a fellowship in urologic oncology, and he is comprehensively trained in open, laparoscopic and robotic approaches to surgical treatment of urologic cancer. He balances his clinical practice with a passion for health services research, a topic that addresses cost, quality and efficiency of healthcare. His research focuses on life expectancy and its role in treatment decision-making for men with early stage prostate cancer. His work promotes a more personalized approach to care to reduce unnecessary overtreatment, while targeting treatment to those who need it. Dr. Daskivichv has published in Annals of Internal Medicine, Cancer, Archives of Internal Medicine, and the Journal of Urology. His nationally recognized work has received funding from the American Cancer Society and the American Urological Association. Dr. Daskivich's research efforts are highly integrated into his clinical practice, with the overarching goal of optimizing both cure of cancer and quality of life for his patients.

• Undergraduate: Harvard College, 2001
• Medical School: Harvard Medical School, 2006
• Residency: UCLA David Geffen School of Medicine, 2012
• Master's: UCLA School of Public Health, 2014
• Fellowship: UCLA David Geffen School of Medicine, 2015

View CV as a PDF

• Cancer
• Urologic Oncology
• Urology Academic Practice
• Surgery

• Best Abstract, Society of Urologic Oncology Annual Meeting, 2014
• Board of Directors, Accreditation Council for Graduate Medical Education, 2013-15
• Resident Director, Accreditation Council for Graduate Medical Education, 2013-15
• Collaborator, RAND Urologic Diseases in America Project, 2013
• Best Poster, American Urological Association Annual Meeting, 2012

Click here for a list of peer-reviewed publications.

• Daskivich TJ, Kwan L, Dash A, Litwin MS. An Age-Adjusted Comorbidity Index for Prediction of Other-Cause Mortality in Men with Early-Stage Prostate Cancer. J Urol. 2015;194(1):73-78.
• Daskivich TJ, Lai J, Dick AW, Steodji CM, Hanley JM, Litwin MS, Saigal CS; Urologic Diseases in America Project. Variation in treatment associated with life expectancy in a population-based cohort of men with early-stage prostate cancer. Cancer. 2014;120(23):3642-3650.
• Daskivich TJ, Lai J, Dick AW, Setodji CM, Hanley J, Litwin MS, Saigal, CS; Urologic Diseases in America Project. Comparative effectiveness of aggressive versus non-aggressive treatment for men with early-stage prostate cancer and differing comorbid disease burdens at diagnosis. Cancer. 2014;120:2432-2439.